Despite trepidations, bioprocess oursourcing has come a long way from its inception, which was born in necessity and regulatory fear. Based on primary research that Seraphim and Pharmsource conducted in 2002, the current market for biopharmaceutical manufacturing outsourcing (upstream and downstream production of bulk APIs, but excluding separately outsourced analytics, development, and other services) was $500 to $700 million with a projection to grow to $1.5 to $2.5 billion over the next five years…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.
